Karyopharm at a crossroads: can selinexor and SENTRY turn a single‑asset bet into a durable oncology business?

When Karyopharm Therapeutics went public in 2013, it was selling a scientific idea rather than a product. Founded in 2008, the Massachusetts-based biotech was built around a focused thesis: that blocking a cellular gatekeeper called exportin 1, or XPO1, could rein in cancer cells by trapping key regulatory proteins inside the nucleus where they can do their job. The company’s Selective Inhibitor of Nuclear Export, or SINE, compounds were a bet that this one target could touch many tumor-driving pathways at once.

That target, XPO1, acts as a transport protein. In healthy cells, it shuttles certain proteins from the nucleus, where DNA is housed, out into the rest of the cell. Many of those cargo proteins are tumor suppressors, responsible for detecting damage and triggering repair or cell death. Cancer cells often hijack XPO1, exporting these safeguards out of the nucleus and effectively disabling them. Karyopharm’s idea was simple to describe but hard to execute: design small molecules that bind XPO1 and block that export process, forcing tumor suppressors to remain in the nucleus and reassert control.

In plain terms, Chief Medical Officer Reshma Rangwala’s description means that by targeting XPO1, Karyopharm hopes to pull several levers at once. Rather than designing a separate drug for each signaling pathway that cancer cells exploit, the company is trying to choke off a central route that many of those signals depend on. The lead compound, selinexor, was the first of these SINE molecules to move from concept to clinic.

Selinexor selectively binds to XPO1 and blocks the export of critical regulatory proteins out of the nucleus. In preclinical models, that mechanism restored the activity of tumor suppressors and led to cancer cell death. It also produced a recognizable side-effect profile, including nausea and low blood counts, that would trail the drug into the clinic and shape dosing strategies.

Over the 2010s, Karyopharm pushed selinexor through a sequence of early- and mid-stage trials, initially in blood cancers where the biology of nuclear export seemed especially relevant and where regulators have historically been more receptive to targeted agents with strong response data. By 2020, that strategy had paid off with U.S. approvals for selinexor, branded as XPOVIO, in multiple myeloma and in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In Europe and other territories, the drug is commercialized as NEXPOVIO through a licensing partnership.

Along the way, Karyopharm evolved from a pure development-stage biotech into a commercial-stage oncology company, albeit one still defined by a single mechanism and a single lead asset. The pipeline filled out with additional XPO1 inhibitors such as eltanexor, designed to tweak the balance between potency and tolerability, but selinexor remained the workhorse that would have to fund experimentation elsewhere in the portfolio.

Leadership also shifted to fit that transition. Chief Executive Officer Richard Paulson now frames Karyopharm as a late-stage company entering a defining phase. Rangwala leads clinical development and often serves as the scientific explainer in chief on earnings calls. On the commercial side, senior leadership is focused on extracting as much value as possible from XPOVIO’s existing indications and preparing for potential expansion into new ones. The finance team oversees a balance sheet that has become central to the Karyopharm story, while investor relations works to translate complex clinical updates into a coherent narrative for a skeptical capital market.

By 2020, Karyopharm’s thesis had become tangible. Selinexor received U.S. approvals for adult patients with multiple myeloma and for those with relapsed or refractory DLBCL, two hematologic malignancies where treatment options narrow as patients cycle through lines of therapy. In multiple myeloma, XPOVIO is used in combination regimens in later lines, slotting into a crowded ecosystem of proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies and newer cell-based therapies. In DLBCL, the drug serves as an option for patients whose disease has returned or not responded to prior treatments.

Inside Karyopharm, these indications do more than validate the science. They form the commercial backbone that pays for the rest of the pipeline. On a February 2026 earnings call, Paulson described it succinctly: "Today, selinexor has an established durable commercial foundation in multi myeloma within a highly competitive treatment landscape." That durability is essential, because multiple myeloma sales represent the core recurring revenue stream that must support R&D in riskier late-stage programs like myelofibrosis and endometrial cancer.

Branding reflects that ambition to turn a mechanism into a franchise. XPOVIO is the U.S. trade name for selinexor, while NEXPOVIO is used in Europe and other licensed markets. Karyopharm chose to partner outside its home turf rather than build a costly international sales infrastructure. Under a license agreement with Menarini Group, an Italian pharmaceutical company with a global footprint, Menarini develops and commercializes NEXPOVIO for human oncology indications across Europe, including the United Kingdom, Latin America and other territories.

For a small cap like Karyopharm, that structure trades a portion of revenue for speed and capital efficiency. Menarini brings established local relationships with oncologists, reimbursement authorities and hospital systems, while Karyopharm captures royalties and potential milestones without the upfront expense of field forces across dozens of countries. It is a standard biotech move, but in this case it is tightly linked to the company’s financial profile.

That profile features a striking figure: across recent quarters, Karyopharm’s gross margins on product sales have hovered around 95 to 97 percent. In Q1 2026, gross margin stood at roughly 96.1 percent, slightly above Q4 2025’s 95.6 percent and close to Q2 2025’s 97.2 percent. In simple terms, once the company manufactures and ships a pill, the gap between selling price and production cost is wide. On a per-unit basis, selinexor is a lucrative product.

The commercial team’s task is to turn that unit economics into a mature franchise. That means educating hematologists on where XPOVIO fits, navigating payer dynamics as newer therapies compete for later-line patients, and looking for opportunities to move earlier in the treatment paradigm where patient numbers are larger. It also means preparing the same channels to support possible label expansions if selinexor succeeds in other indications.

At the moment, that expansion story is framed around two high-stakes Phase III programs: SENTRY in myelofibrosis and XPORT-EC-042 in endometrial cancer. If those trials read out positively and lead to approvals, the multiple myeloma business will serve as the base that absorbs the upfront launch costs. If they stumble, the same business will have to carry the weight of a disappointed pipeline in a field where competition continues to intensify.

Recent revenue trends show both the promise and constraints of that backbone. In Q1 2026, Karyopharm reported $35.07 million in revenue, up 2.9 percent from $34.08 million in Q4 2025 but down about 20.4 percent from $44.04 million in Q3 2025. That volatility underlines a key point: even with an approved product in two indications and an ex-US partner, the company’s commercial base is not yet large or stable enough to fund its ambitions without external capital.

The real hinge in Karyopharm’s story today lies not in multiple myeloma but in myelofibrosis and endometrial cancer. These are the late-stage programs that, if successful, could reposition the company from a single-asset myeloma player to a broader oncology firm with a multi-indication franchise built on XPO1 inhibition.

On May 14, 2026, that hinge moved. Investors dialed into the Q1 earnings call expecting more than quarterly numbers. Karyopharm had promised top-line results from SENTRY, its Phase III trial testing selinexor in combination with ruxolitinib, the current standard-of-care JAK inhibitor, in patients with myelofibrosis. The condition is a chronic bone marrow cancer in which scar tissue (fibrosis) disrupts normal blood cell production, leading to anemia, enlarged spleen and debilitating symptoms.

Current JAK inhibitors like ruxolitinib can shrink spleen size and ease symptoms for many patients, but they are not widely viewed as disease-modifying. They do not fully address the underlying biology that drives fibrosis and progression. As Rangwala put it earlier in the year, "JAK inhibitors are the only approved therapies. And while they may decrease symptom burden and lead to very modest spleen reduction, relevant JAK inhibitors, including ruxolitinib, the standard of care in frontline myelofibrosis do not target all of the relevant pathways implicated in myelofibrosis, including NF-kappa beta, p53 and fibrosis-inducing pathways."

SENTRY was designed to test whether adding selinexor’s multi-pathway mechanism to ruxolitinib could improve outcomes meaningfully. The study’s co-primary endpoints included spleen volume reduction of at least 35 percent (SVR35) at week 24, a standard metric for assessing response in myelofibrosis. According to Rangwala, "The co-primary endpoint of SVR35 at week 24 was 50% for the combination compared to 28% for ruxolitinib alone, corresponding to a statistically significant p-value of less than 0.0001." In other words, patients receiving selinexor plus ruxolitinib were nearly twice as likely to achieve this level of spleen shrinkage as those on ruxolitinib alone.

Just as important for oncologists, the responses were described as rapid, deep and sustained. Paulson summarized the topline: "SENTRY showed a compelling and differentiated profile for selinexor in combination with ruxolitinib, including rapid, deep and sustained spleen volume responses accompanied by a promising overall survival signal and evidence of potential disease modification, including greater reductions in variance frequency as early as week 24." The company has highlighted that these data earned a slot as a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) meeting, with a peer-reviewed manuscript expected in mid-2026.

That "promising overall survival signal" is where the story could become transformative. In oncology, overall survival, or OS, is the length of time from treatment start until death from any cause. It is often regarded as the clearest indicator of clinical benefit. In SENTRY, the combination of selinexor and ruxolitinib produced an overall survival hazard ratio of 0.43 compared with ruxolitinib alone. A hazard ratio below 1 suggests a reduction in the risk of death; 0.43 implies a 57 percent relative reduction in that risk over the follow-up period.

Rangwala went further in framing the significance: "The combination of selinexor and ruxolitinib is the first potential treatment in myelofibrosis to suggest an overall survival improvement relative to standard of care." In a field where incremental gains have been the norm, that raises expectations. For regulators and payers, though, the details will matter: durability of the signal, consistency across subgroups and the balance between efficacy and tolerability, given selinexor’s known side effects.

From an investor’s perspective, SENTRY is more than a scientific milestone. It is a potential inflection point for the company’s revenue mix and negotiating leverage. A frontline myelofibrosis indication could significantly expand the addressable market for selinexor, especially if the survival advantage holds up under full peer review. It could also strengthen Karyopharm’s hand in seeking partnerships or co-commercialization deals in geographies where it lacks infrastructure, as it did with Menarini for NEXPOVIO.

Paulson has been explicit about where he sees value concentrating. "Looking ahead, we see the most significant near-term driver of value in myelofibrosis with endometrial cancer representing a subsequent opportunity to further expand the franchise," he told investors in February. That endometrial program, XPORT-EC-042, is the second decisive bet in Karyopharm’s late-stage pipeline.

Endometrial cancer, a tumor of the uterine lining, has seen a flurry of activity from immuno-oncology and targeted therapies, but relapse and resistance remain common problems. XPORT-EC-042 is a Phase III trial testing selinexor-based regimens in certain endometrial cancer settings, aiming to improve progression-free survival, the period during which a patient lives without the disease getting worse. As of the May 2026 call, enrollment was complete and the study remained on track for a mid-2026 top-line readout.

Rangwala’s enthusiasm captures the strategic stakes. If XPORT-EC-042 delivers a clear benefit and the SENTRY data mature as hoped, Karyopharm could find itself with two late-stage programs poised to reshape standard of care in both a hematologic malignancy and a solid tumor. That, in turn, could diversify its revenue beyond multiple myeloma, strengthen its case for pricing and open doors to additional collaborations.

The flip side is equally important. If XPORT-EC-042 underwhelms or is delayed, the company’s near-term growth narrative would rest almost entirely on myelofibrosis, magnifying the importance of every additional cut of SENTRY data. And if regulatory agencies view the survival signal more cautiously than Karyopharm hopes, the drug’s label and uptake could fall short of current expectations. In a company so tightly tied to one target, the binary nature of these readouts shapes the entire risk profile.

The scientific narrative around SENTRY and XPORT-EC-042 is ambitious. The financial narrative is more fragile. On the same May 14 call where Karyopharm unveiled headline SENTRY data, slides also showed a company still losing more than $22 million a quarter, with a balance sheet built on borrowed money and fresh equity rather than retained earnings.

In Q1 2026, Karyopharm generated $35.07 million in revenue, a modest 2.9 percent increase over the prior quarter’s $34.08 million but well below the $44.04 million reported in Q3 2025. Despite that revenue base and a gross margin of about 96.1 percent, the company posted an operating loss of $26.76 million, wider than the $17.84 million operating loss in Q4 2025 and the $15.22 million loss in Q3 2025.

The company’s net loss narrowed to $22.39 million from a steep $102.20 million in Q4 2025 and $37.25 million in Q2 2025, helped in part by non-recurring items and financing effects. But the core picture remains one of a business that has not yet reached scale. Research and development, along with selling, general and administrative expenses, continue to outstrip gross profit, producing negative free cash flow from operations of $22.73 million in Q1 2026.

On the balance sheet, the numbers are starker. As of March 31, 2026, Karyopharm reported $90.85 million in cash and short-term investments, up from $63.74 million at December 31, 2025 and $45.88 million at September 30, 2025. That increase did not come from operations; it came from capital markets. The company completed a financing transaction in the first quarter of 2026 that boosted liquidity, contributing to a rise in cash despite continued negative free cash flow.

Total debt has marched upward as well, from $190.62 million at June 30, 2025 to $196.42 million at September 30, 2025 and $230.87 million at March 31, 2026. With persistent losses, stockholders’ equity has remained negative, standing at about -$265.65 million at the end of Q1 2026. Key profitability metrics tell the same story: return on assets has been negative in each recent quarter, at around -0.17 in Q1 2026 versus -0.94 in Q4 2025 and -0.35 in Q2 2025.

For investors, these figures crystallize the core financial risk: Karyopharm is financing the runway to its pivotal data and potential launches with a mix of equity and debt. Each quarter of negative free cash flow chips away at its cash position. Each new financing lifts the debt balance or dilutes existing shareholders. The key question is whether the SENTRY and XPORT-EC-042 results can arrive, and convert into regulatory and commercial outcomes, before the company needs to return to capital markets on less favorable terms.

Paulson has tried to reassure investors that management is not blind to these constraints. The repeated emphasis on "discipline" and "sequencing" speaks to a strategy of pacing trial spending, launch preparation and commercial investment around key inflection points. In practice, that means prioritizing SENTRY and XPORT-EC-042 above earlier-stage experiments and being selective about new initiatives until more data firm up the growth trajectory.

Still, the arithmetic is hard to ignore. With quarterly operating losses in the mid-twenty millions and a cash balance under $100 million as of March, Karyopharm’s runway to late 2026 and beyond is uncertain without additional capital or a meaningful shift in cash generation. High gross margins are helpful, but they cannot overcome the scale of R&D and SG&A spend unless revenue grows materially.

Against this backdrop, Karyopharm’s near-term path is defined by a tightly packed set of clinical, regulatory and financial milestones. For investors trying to assess whether the company is at an inflection point or just another stop on a long development road, the next 12 to 24 months will be critical.

On the clinical front, SENTRY’s late-breaking oral presentation at ASCO will be the first public stress test for the myelofibrosis data. Beyond the headline SVR35 rates of 50 percent versus 28 percent and the overall survival hazard ratio of 0.43, oncologists will look for deeper cuts: subgroup analyses by risk category, mutational status and prior JAK exposure; duration of response curves; and safety data that indicate how tolerable selinexor is when combined with ruxolitinib in everyday practice.

The peer-reviewed manuscript Karyopharm expects in mid-2026 will serve as a second validation layer. Journal reviewers and clinicians will scrutinize trial conduct, statistical methods and the robustness of the survival signal. If the data stand up, the company can move more confidently toward regulatory discussions, including the potential for expedited pathways if agencies view the regimen as addressing a significant unmet need.

Parallel to that, XPORT-EC-042 in endometrial cancer is approaching its own moment of truth. Calibrating expectations will be important: unlike myelofibrosis, where standard of care has changed more gradually, endometrial cancer has seen rapid evolution in immuno-oncology and targeted combinations. Demonstrating a clear progression-free survival benefit, and ideally an overall survival trend, in this competitive context may be harder. But even a well-defined niche role could add a new revenue stream and reinforce the notion of selinexor as a versatile oncology agent.

Paulson’s articulation of those three priorities offers a simple framework for monitoring execution. First, on advancing late-stage programs, investors will want to see timely ASCO presentation and manuscript publication for SENTRY; clear communication of regulatory plans in myelofibrosis; and on-schedule top-line data from XPORT-EC-042 in mid-2026, followed by any indication of filing timelines. Slippage or ambiguity on these fronts would raise questions about both operational capacity and ultimate market impact.

Second, maintaining the commercial foundation in multiple myeloma and DLBCL means stabilizing and, ideally, growing XPOVIO/NEXPOVIO revenue. Metrics to watch include quarterly revenue trends, especially relative to the Q3 2025 high-water mark of $44.04 million; gross margin maintenance at or above the mid-90s; and any signs of market share erosion as newer therapies enter later-line myeloma. The performance of the Menarini partnership ex-US will also be an indicator of global franchise health.

Third, disciplined business management comes down to cash. Here, the checklist is straightforward: operating loss trajectory; free cash flow from operations; cash and short-term investments relative to quarterly burn; and evolution of total debt and stockholders’ equity. Persistent operating losses in the mid-twenty million range with flat revenue would suggest further financings are likely, whereas visible operating leverage would support the case for eventual self-funding growth.

Risk, inevitably, is concentrated around selinexor and the broader XPO1 thesis. Mechanistically, XPO1 inhibition remains an attractive concept: by preventing tumor suppressor proteins from exiting the nucleus, selinexor aims to restore multiple control pathways at once. Rangwala has emphasized this multi-pathway effect as a differentiator compared with agents that focus on a single signaling axis. But scientifically elegant ideas do not always map neatly onto commercial success, especially when tolerability, competition and payer dynamics intervene.

Pipeline concentration is another issue. While Karyopharm has other XPO1 inhibitors such as eltanexor, as well as earlier-stage candidates, the vast majority of current and near-term value is tied to selinexor. That magnifies both upside and downside. A string of positive data, approvals and launches could compound into a durable franchise, while setbacks in any one of the major programs would reverberate across the rest of the portfolio and the company’s financing options.

Competition looms in both target indications. In myelofibrosis, several players are pursuing combination strategies that layer new mechanisms on top of JAK inhibition, from BET inhibitors to novel signaling modulators. If multiple agents show survival signals, differentiation will come down to effect size, safety and practical considerations like oral dosing schedules and support needs. In endometrial cancer, accelerated approvals and combination regimens have raised the bar for what counts as a practice-changing therapy.

For now, Karyopharm is leaning into its identity as a focused oncology company willing to make concentrated bets. "Karyopharm continues to execute through an important period for the company with the recent and upcoming milestones that we believe can unlock meaningful growth opportunities and shape our next phase," Paulson told investors on the Q1 2026 call. The coming phase will test whether that execution can keep up with the science and the spend.

Ultimately, the question that opened this article remains unresolved. SENTRY’s Phase III data, headlined by an SVR35 rate of 50 percent versus 28 percent and an overall survival hazard ratio of 0.43, look like the kind of results that can change treatment practice, at least on their surface. XPORT-EC-042’s mid-2026 top-line readout offers a second shot at redefining selinexor’s reach in a solid tumor. Together, they represent the company’s best chance to transition from a high-potential, cash-burning biotech into a more sustainable oncology business.

Whether that transition happens will depend on more than p-values and hazard ratios. It will hinge on regulatory interpretations of survival signals, physician comfort with selinexor’s benefit-risk profile, payer willingness to reimburse and management’s ability to sequence spending without outrunning its balance sheet. For investors watching Karyopharm, the next chapters will show whether the company’s long-running bet on XPO1 inhibition finally tilts the odds in its favor, or whether the clock on its fragile finances runs down before the science can fully pay off.